Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pioneering Study on the Safety and Efficacy of CD147-Chimeric Antigen Receptor (CAR) T Cells in Patients With Relapsed or Refractory T-cell Non-Hodgkin's Lymphoma

NCT05013372 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT05013372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05013372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pioneering Study on the Safety and Efficacy of CD147-Chimeric Antigen Receptor (CAR) T Cells in Patients With Relapsed or Refractory T-cell Non-Hodgkin's Lymphoma
Lead sponsor
Peking University People's Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
January 31, 2023
Completion date
January 1, 2025
Enrollment
12 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell non-hodgkin's lymphoma